Roche Holding AG (OTCMKTS:RHHBY) Short Interest Update

Roche Holding AG (OTCMKTS:RHHBY) was the target of a large decline in short interest in September. As of September 30th, there was short interest totalling 2,593,100 shares, a decline of 27.4% from the September 15th total of 3,574,200 shares. Based on an average daily volume of 2,237,300 shares, the days-to-cover ratio is currently 1.2 days.

Hedge Funds Weigh In On Roche

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AlphaMark Advisors LLC purchased a new position in shares of Roche during the first quarter valued at $34,000. GAMMA Investing LLC increased its holdings in shares of Roche by 61.5% in the 2nd quarter. GAMMA Investing LLC now owns 5,038 shares of the company’s stock valued at $175,000 after purchasing an additional 1,919 shares during the period. Archer Investment Corp lifted its position in shares of Roche by 10.6% in the second quarter. Archer Investment Corp now owns 6,810 shares of the company’s stock worth $236,000 after purchasing an additional 652 shares in the last quarter. Waldron Private Wealth LLC acquired a new stake in shares of Roche during the second quarter worth approximately $263,000. Finally, Lee Danner & Bass Inc. purchased a new position in Roche during the second quarter valued at approximately $327,000.

Roche Stock Performance

Shares of Roche stock traded down $0.01 during trading on Monday, hitting $39.17. The stock had a trading volume of 1,991,463 shares, compared to its average volume of 2,207,538. Roche has a 1 year low of $29.20 and a 1 year high of $42.43. The stock has a 50 day simple moving average of $40.00 and a 200 day simple moving average of $35.80.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on RHHBY. Bank of America upgraded shares of Roche from a “neutral” rating to a “buy” rating in a report on Friday, September 13th. Deutsche Bank Aktiengesellschaft lowered Roche from a “hold” rating to a “sell” rating in a research note on Friday, September 13th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Roche presently has an average rating of “Hold”.

About Roche

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.